Skip to main content
Premium Trial:

Request an Annual Quote

GoPath Labs to Commercialize IntegraGen Cancer Therapy Biomarker Test

NEW YORK (GenomeWeb) – IntegraGen and GoPath Laboratories said today that they have signed a non-exclusive licensing agreement under which GoPath plans to commercialize a test based on IntegraGen's proprietary miR-31-3p biomarker in the US and Canada.

IntegraGen has already made an miR-31-3p kit available as a CE-IVD-marked test in Europe. It's designed to help clinicians identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

"Based on published clinical data which demonstrates the ability of miR-31-3p to proactively identify RAS wild-type metastatic colorectal cancer patients who will have increased benefit from treatment with anti-EGFR therapy, we feel the miR-31-3p expression test will complement our existing test offering for this patient population," GoPath Founder and CEO Jim Lu said in a statement.

Lu added that the company is planning to make the test available to clinicians within the year, after completing validation steps in its Illinois laboratory.

Financial terms of the deal were not disclosed.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.